Aurobindo Pharma Peer Comparison

Aurobindo Pharma Ltd. demonstrates robust growth and solid profitability metrics, positioning it as a competitive player in the Pharmaceuticals & Drugs industry. While it faces competition from strong performers like Dr. Reddy's Laboratories and Cipla, its low debt levels and moderate PE ratio make it an attractive investment relative to some peers, despite the overall sector facing valuation challenges.

• • Aurobindo Pharma shows strong revenue growth of 16.68% YoY and solid profitability with a 10.93% profit margin.
• • Dr. Reddy's Laboratories stands out with the highest ROE at 21.76%, while Sun Pharma has the lowest PE at 87.59, indicating overvaluation.
• • Cipla is a best value pick with a low PE ratio of 23.73 and high profitability metrics.

• • Dr. Reddy's Laboratories Ltd.: Highest ROE at 21.76% and solid EPS growth, showcasing strong profitability.
• • Cipla Ltd.: Lowest PE ratio at 23.73, high ROA and ROCE indicating efficient use of capital.
• • Mankind Pharma Ltd.: Strong revenue growth of 18.12% YoY and a high ROE of 23.15%, signaling effective growth strategy.